AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Blue Sky Alternative Inv

0.185

0.000

Volume:- -

Turnover:- -

Market Cap:14.38M

PE:-0.13

High:0.185

Open:0.185

Low:0.185

Close:0.185

52wk High:0.185

52wk Low:0.185

Shares:77.71M

Float Shares:73.88M

Volume Ratio:0.93

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.396

EPS(LYR):-0.992

ROE:-82.95%

ROA:-18.76%

PB:0.13

PE(LYR):-0.19

Loading ...

Overview Company News Filings

Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

A Look At Axogen (AXGN) Valuation After Its Upsized Equity Offering And Share Price Rally

Simply Wall St.

Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma

Vera Therapeutics (VERA) Is Up 12.5% After Atacicept BLA Filing and Positive Phase 3 Data

Simply Wall St.

Will Hopes for Lower Rates and Easing Tensions Shift Shoals Technologies Group's (SHLS) Story?

Simply Wall St.

Why Is Shoals (SHLS) Stock Rocketing Higher Today

stock_story_highlight

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BLA.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BLA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BLA.AU\",,,,,undefined,":{"symbol":"BLA.AU","market":"AU","secType":"STK","nameCN":"Blue Sky Alternative Inv","latestPrice":0.185,"timestamp":1773982800000,"preClose":0.185,"halted":3,"volume":0,"delay":0,"changeRate":0,"nameEN":"Blue Sky Alternative Inv","floatShares":73880053,"shares":77711527,"eps":-1.395589,"marketStatus":"Halted","change":0,"latestTime":"03-20 16:00:00 AEDT","open":0.185,"high":0.185,"low":0.185,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.395589,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774220400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.185,"openAndCloseTimeList":[[1773961200000,1773982800000]],"volumeRatio":0.9266472334628041,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BLA.AU\",,,,,undefined,":{"symbol":"BLA.AU","floatShares":73880053,"roa":"-18.76%","roe":"-82.95%","lyrEps":-0.991856,"volumeRatio":0.9266472334628041,"shares":77711527,"dividePrice":0,"high":0.185,"amplitude":0,"preClose":0.185,"low":0.185,"week52Low":0.185,"pbRate":"0.13","week52High":0.185,"institutionHeld":0,"latestPrice":0.185,"eps":-1.395589,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.395589,"open":0.185,"prevYearClose":0.185,"prevWeekClose":0.185,"prevMonthClose":0.185,"prevQuarterClose":0.185,"fiveDayClose":0.185,"twentyDayClose":0.185,"sixtyDayClose":0.185},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BLA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BLA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BLA.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620896241","title":"Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China","url":"https://stock-news.laohu8.com/highlight/detail?id=2620896241","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620896241?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:27","pubTimestamp":1773916020,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed  today announced that BBM-H901 , has been officially approved by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of China for the treatment of adult patients with moderate to severe hemophilia B . This product is developed and manufactured by BBM, and Takeda China is responsible for its commercialization in mainland China, Hong Kong, China and Macao, China. Following its approval in mainland China in April 2025 as the country's first gene therapy for hemophilia B, [1] the recent approval of BBM-H901 in Macao, China, not only addresses the previously unmet medical need for such treatment in the region but also marks a crucial step in accelerating the global availability of this breakthrough gene therapy.BBM-H901 is a gene therapy drug based on a recombinant adeno-associated virus  vector. It can precisely deliver the high-activity FIX gene into the liver cells of patients, enabling the sustained and h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/belief-biomed-announced-bbm-h901-dalnacogene-ponparvovec-injection-chinas-first-hemophilia-b-gene-therapy-was-officially-approved-in-macao-china-302718633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLA.AU","BK4081","LU0963586101.USD","BK4129","ATMP","EMA","BK7057","ASH.AU","LU0054578231.USD","ODD","BK4567","IE0009354923.USD","BK4110","LU2463526074.USD","BK7095","BK4183","ABR","EMA.AU","ABR.AU","BK4109","BK7504","BK7129","LU0053671581.USD","FIX","ASH"],"gpt_icon":0},{"id":"2612231047","title":"FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612231047","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612231047?lang=en_us&edition=fundamental","pubTime":"2026-02-20 07:27","pubTimestamp":1771543620,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces its financial results for the year ended December31, 2025.Group performance2: Double-digit revenue growth and positive adjusted operating cash flow. Revenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4.US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance.Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure and research and development (R&D).Year-end cash balance of US$141.9 million following US$246.4 million of strategic investments (M&A) and cash generated from operating activities of US$34.5 million before the final contingent consideration payment to Advanced Nuclear Medicine Ingredients  of US$51.8 million7","market":"sg","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fy-2025-results-strong-commercial-growth-focused-pipeline-investment-302693191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7116","ASX","BK7039","BK4543","BK7067","TAT","TAT.AU","BLA.AU","BK7506","ASX.AU","BK4109","BK4585","BK7104","GBM.AU","TMS.AU","BK4141","BK7095","BK4526","TLX","BK4588","CE","BK4139","SEC.AU"],"gpt_icon":0},{"id":"2606255148","title":"A Look At Axogen (AXGN) Valuation After Its Upsized Equity Offering And Share Price Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2606255148","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606255148?lang=en_us&edition=fundamental","pubTime":"2026-01-25 10:39","pubTimestamp":1769308742,"startTime":"0","endTime":"0","summary":"Axogen (AXGN) has quickly moved from announcing a US$85 million follow on equity offering to completing an upsized US$124 million share sale at US$31, a shift that directly affects existing shareholders.\nSee our latest analysis for Axogen.\nThe upsized offering and share sale come after Axogen issued upbeat preliminary 2025 revenue guidance. The stock has responded with strong momentum, including a 90 day share price return of 84.75% and a 3 year total shareholder return of 221.55%. This...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-axgn/axogen/news/a-look-at-axogen-axgn-valuation-after-its-upsized-equity-off","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-axgn/axogen/news/a-look-at-axogen-axgn-valuation-after-its-upsized-equity-off","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4082","BK4215","BLA.AU","BK4585","EQR","BK4588","AXGN"],"gpt_icon":0},{"id":"2605144430","title":"Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2605144430","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605144430?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:00","pubTimestamp":1768946400,"startTime":"0","endTime":"0","summary":"Japan's Ministry of Health, Labour and Welfare  grants MCO-010 Sakigake  and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases. Enhances strong global regulatory momentum, including multiple FDA expedited programs and five EMA Orphan designations. FDA, EMA and PMDA conditionally approve the MOGENRY brand name. Strengthens global pre-commercialization readiness and reinforces leadership in optogenetic therapy. DALLAS, Jan. 21, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company developing disease-agnostic therapies for vision loss caused by retinal degeneration, today announced that Japan's Ministry of Health, Labour and Welfare  has granted both Sakigake  and Orphan Drug designations to MCO-010, its lead optogenetic therapy for patients with severe vision loss from inherited retinal dystrophies . Approximately 50,000 patients in Japan are affected by IRDs.The MHLW decision builds on strong reg","market":"us","thumbnail":"https://mma.prnewswire.com/media/2718911/NSCOPE_nu_Horizontal_2Color_1200px_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2718911/NSCOPE_nu_Horizontal_2Color_1200px_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/nanoscope-secures-japan-mhlw-sakigake-and-orphan-drug-designations-across-inherited-retinal-diseases--a-first-for-a-retinal-gene-therapy-302665003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK7129","EMA.AU","BK4081","BLA.AU"],"gpt_icon":0},{"id":"2603620144","title":"Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2603620144","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603620144?lang=en_us&edition=fundamental","pubTime":"2026-01-15 12:11","pubTimestamp":1768450260,"startTime":"0","endTime":"0","summary":"SHANGHAI, Jan. 15, 2026 /PRNewswire/ -- AskBio Inc. , a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration  has accepted its Investigational New Drug  application for AB-1009, an investigational adeno-associated virus  gene therapy being developed for the treatment of late-onset Pompe disease. With this announcement, the AB-1009 program advances to Phase 1/2, and AskBio initiates a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting its first patient in early 2026 [1].In September 2024, Belief BioMed  and AskBio entered astrategic collaboration to explore the potential for new gene therapies [2]. BBM granted AskBio a sublicense to use the proprietary AAV capsid in the AB-1009 program and provided AAV vector production services. Within the collaborative development framework, BBM worked closely with the AskBio team, and its co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/belief-biomed-congratulates-partner-askbio-on-ind-acceptance-by-fda-for-investigational-gene-therapy-for-late-onset-pompe-disease-302661902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","BK7095","BLA.AU","GAA","IND"],"gpt_icon":0},{"id":"2592967216","title":"Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol","url":"https://stock-news.laohu8.com/highlight/detail?id=2592967216","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592967216?lang=en_us&edition=fundamental","pubTime":"2025-12-17 16:10","pubTimestamp":1765959000,"startTime":"0","endTime":"0","summary":"LEROCHOL is a novel, third-generation PCSK9 inhibitor designed to help patients achieve and maintain their LDL-C targets. It is self-administered as a once-monthly, single small-volume subcutaneous injection with extended room-temperature stability , giving patients the freedom to administer it where and when they choose. These features make LEROCHOL a unique alternative to other PCSK9 inhibitors.The FDA approval of LEROCHOL was based on data from the comprehensive global Phase 3 LIBerate Clinical Trial Program, which enrolled a diverse population of over 2,900 patients with cardiovascular disease , or without but at very high or high risk for CVD, including HeFH.In clinical trials, LEROCHOL demonstrated sustained LDL-C reductions of ≥60% in patients with, or at very-high or high risk of CVD and 59% in those with HeFH who have more severe LDL-C elevations. LEROCHOL was generally well tolerated across the LIBerate Clinical Trial Program. Lerodalcibep is expected to expand treatment opti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-that-licensing-partner-lib-therapeutics-has-received-us-fda-approval-of-lerochol-lerodalcibep-liga-for-adults-with-elevated-ldl-cholesterol-302644459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","EMA","BK4539","EMA.AU","LDL","BK4081","BK4139","BLA.AU","BK7129","MDCO","BK4007"],"gpt_icon":0},{"id":"2590510262","title":"Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten","url":"https://stock-news.laohu8.com/highlight/detail?id=2590510262","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590510262?lang=en_us&edition=fundamental","pubTime":"2025-12-11 23:57","pubTimestamp":1765468620,"startTime":"0","endTime":"0","summary":"- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization- Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to the Company's late-stage product pipeline- Together, these agreements drive financial and strategic synergies, improve utilization and productivity of our existing commercial platform, and strengthen commercial capabilities and life-cycle management, while establishing an attractive vertical in cardiovascular disease. SHANGHAI, Dec. 11, 2025 /PRNewswire/ -- Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that its wholly-owned subsidiary, Everest Medicines  Co., Ltd , has entered into two strategic agreements with privatel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-commercialization-service-agreement-and-license-agreement-with-hasten-302639416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","EMA.AU","BK4081","BK7129","EMA","BLA.AU"],"gpt_icon":0},{"id":"2586743219","title":"IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2586743219","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586743219?lang=en_us&edition=fundamental","pubTime":"2025-11-27 13:44","pubTimestamp":1764222240,"startTime":"0","endTime":"0","summary":"SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ --IASO Biotechnology , a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, today announced that the Biologics License Application  for its independently developed fully human anti-BCMA CAR-T therapy Fucaso  has been approved by the Hong Kong Department of Health. The therapy is indicated for adult patients with relapsed or refractory multiple myeloma  who have received three or more prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent.This approval marks the first authorization of a China-developedCAR-T cell therapy in Hong Kong  and the first China-developedATMP  to obtain PIC/S GMP recognition following Hong Kong DoH inspection. PIC/S  consists of more than 56 regulatory authorities, including the U.S","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/iaso-bio-announces-bla-approval-of-fucaso-equecabtagene-autoleucel-by-the-hong-kong-department-of-health-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-302627347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLA.AU","ATMP"],"gpt_icon":0},{"id":"2583352684","title":"Vera Therapeutics (VERA) Is Up 12.5% After Atacicept BLA Filing and Positive Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2583352684","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583352684?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:27","pubTimestamp":1763148439,"startTime":"0","endTime":"0","summary":"Vera Therapeutics recently announced the submission of a Biologics License Application (BLA) for atacicept to the FDA under the Accelerated Approval Program, supported by positive interim data from the OriginIN 3 trial and late-breaking Phase 3 results presented at ASN Kidney Week and published in The New England Journal of Medicine.\nAn important insight is that atacicept's data highlight both substantial proteinuria reduction and a favorable safety profile, reinforcing its potential as a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/vera-therapeutics-vera-is-up-125-after-atacicept-bla-filing","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/vera-therapeutics-vera-is-up-125-after-atacicept-bla-filing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BLA.AU","BK4539","VERA","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2577343926","title":"Will Hopes for Lower Rates and Easing Tensions Shift Shoals Technologies Group's (SHLS) Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577343926","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577343926?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:36","pubTimestamp":1761165394,"startTime":"0","endTime":"0","summary":"In the past week, Shoals Technologies Group saw attention as investors grew more optimistic due to a combination of encouraging corporate earnings, reduced geopolitical tensions, and hopes for lower future interest rates.\n\n\nDespite some sector commentary on mixed fundamentals, the immediate shift in investor sentiment highlighted Shoals’ close sensitivity to broader macroeconomic and industry news rather than company-specific performance.\n\n\nWe’ll look at how this renewed optimism for...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3051000-choice2-main-header/1585186647175","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3051000-choice2-main-header/1585186647175"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nasdaq-shls/shoals-technologies-group/news/will-hopes-for-lower-rates-and-easing-tensions-shift-shoals","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nasdaq-shls/shoals-technologies-group/news/will-hopes-for-lower-rates-and-easing-tensions-shift-shoals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4096","LU2294711713.HKD","SHLS","LU0823414478.USD","BK4585","LU0823414551.USD","LU2506951792.HKD","BK4588","LU2357125470.USD","LU2249611893.SGD","BLA.AU"],"gpt_icon":0},{"id":"2570708021","title":"Why Is Shoals (SHLS) Stock Rocketing Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2570708021","media":"stock_story_highlight","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570708021?lang=en_us&edition=fundamental","pubTime":"2025-09-25 04:05","pubTimestamp":1758744300,"startTime":"0","endTime":"0","summary":"Shares of solar energy systems company Shoals (NASDAQ:SHLS)\r\n jumped 11.9% in the afternoon session after analysts from JPMorgan Chase & Co. and The Goldman Sachs Group raised their price targets on the stock.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_story_highlight","url":"https://stockstory.org/us/stocks/nasdaq/shls/news/why-up-down/why-is-shoals-shls-stock-rocketing-higher-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockstory.org/us/stocks/nasdaq/shls/news/why-up-down/why-is-shoals-shls-stock-rocketing-higher-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_story_highlight","symbols":["LU0106831901.USD","LU2237443622.USD","LU0048573561.USD","LU0823414478.USD","LU1668664300.SGD","SHLS","IE0004091025.USD","BK4552","TLTW","IE00B19Z3581.USD","LU2471134523.USD","LU2750360997.AUD","BK4585","US7Y.BOND","LU2237443465.HKD","LU2265009873.SGD","LU1868837136.USD","LU2237443978.SGD","LU0742534661.SGD","LU0823414551.USD","IE00B19Z3B42.SGD","US2Y.BOND","LU1791807156.HKD","IE0004086264.USD","LU1804176565.USD","TMF","LU1868836757.USD","LU1868837300.USD","US12M.BOND","LU2471134952.CNY","US6M.BOND","BK4516","US5Y.BOND","LU0251131958.USD","LU2237438978.USD","LU2237443382.USD","US10Y.BOND","LU1868836591.USD","LU2237443895.HKD","LU0061475181.USD","US3Y.BOND","US30Y.BOND","BK4588","BLA.AU","LU2750360641.GBP","BK4550","BK4096","LU1894683348.USD","BK4504"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}